Abstract

This in-silico feasibility analysis discloses, as defensive prior art (CC BY 4.0), a hypothetical lyophilized presentation of aluminium-adjuvanted (alum) vaccines designed to remove the 2-8 C cold chain on which hepatitis A/B, DTaP, HPV, and pneumococcal-conjugate vaccines depend. No wet-lab antigen-binding, immunogenicity, or stability data are generated; all numerical predictions are computational extrapolations from peer-reviewed parameters. The dominant elevated-temperature failure mode is identified as antigen denaturation and irreversible aggregation, destroying conformational epitopes, rather than the slower aluminium-oxyhydroxide crystallization. The formulation embeds commercial Alhydrogel-grade aluminium oxyhydroxide carrying the adsorbed antigen in an amorphous trehalose-pullulan glass (about 80/15 w/w), reconstituted on use. Feasibility is assessed through five analyses: an antigen-denaturation activation-energy Bayesian prior from published vaccine thermal kinetics (Brandau 2003; Plotkin's Vaccines; Lloyd & Cheyne 2017); a PyMC NUTS posterior per representative antigen (HBV surface antigen lead, DTaP comparator); a Couchman-Karasz mixed-glass Tg (about 75-85 C anhydrous); a Tang-Pikal lyophilization-cycle design (shelf <= -30 C, <= 60 mTorr); and a trehalose-protein / adjuvant-antigen molecular-dynamics literature synthesis. The benefit is a low-cost, off-patent, cold-chain-independent vaccine presentation kept in the public domain. Acknowledged prior art (GSK RTS,S/AS01 co-lyophilization, Fortpied 2020; WHO PQS landscape) is non-overlapping with the trehalose-pullulan plus commercial-Alhydrogel combination; no incoherent 110 C AlOH pre-treatment is claimed. ICH Q1A/Q5C real-time data are absent. This is a prior-art disclosure, not deployment, regulatory, or clinical guidance.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Share

COinS